What is OncoDiag?
OncoDiag is a French biotechnology firm headquartered in Normandy, dedicated to advancing the field of oncology diagnostics. The company's core mission revolves around the creation of non-invasive tests designed for the early identification of various cancers. Its flagship product, the Urodiag® (CE-IVD), is a laboratory-based urine test specifically developed for the surveillance of bladder cancer. Beyond this, OncoDiag's product pipeline includes the Prostadiag® test, aimed at predicting non-evolutive localized prostate cancer, and the Colodiag® test, intended for the screening of colorectal cancer. The company's focus on early detection and non-invasive methods positions it as a key player in the evolving landscape of cancer diagnostics.
How much funding has OncoDiag raised?
OncoDiag has raised a total of $3M across 1 funding round:
Series A
$3M
Series A (2021): $3M with participation from Angels Santé, Les Business Angels des Grandes Ecoles, and Normandie Business Angels
Key Investors in OncoDiag
Angels Santé
Angels Santé is an angel investor group likely focused on early-stage healthcare and biotechnology ventures, providing crucial seed capital for innovative companies.
Les Business Angels des Grandes Ecoles
Les Business Angels des Grandes Ecoles is an investment network comprising alumni from prestigious French 'Grandes Écoles', typically investing in promising startups with strong technological or scientific foundations.
Normandie Business Angels
Normandie Business Angels is a regional network supporting startups and SMEs within the Normandy region, likely focusing on companies with significant growth potential and local economic impact.
What's next for OncoDiag?
With the recent major strategic investment, OncoDiag is poised for accelerated growth and further development of its innovative diagnostic solutions. This backing is expected to fuel advancements in clinical validation, regulatory approvals, and market expansion for its existing products like Urodiag® and its promising pipeline candidates, Prostadiag® and Colodiag®. The company's strategic focus on non-invasive cancer detection aligns with global healthcare trends, suggesting a strong trajectory for future success and potential for further capital raises as it scales its operations and brings new tests to market.
See full OncoDiag company page
